Conference Track

Lymphomas

Source: CCO Independent Conference Coverage of the American Society of Hematology 2007 Annual Meeting*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Capsule Summaries

Lenalidomide Shows Activity in Relapsed/Refractory Non-Hodgkin’s Lymphomas
Good Outcome With Intensive Immunochemotherapy With in Vivo Purged Stem Cell Support in Patients With Mantle Cell Lymphoma
In Interim Analysis, Bendamustine Plus Rituximab Comparable to CHOP Plus Rituximab in First-Line Treatment of Patients With Indolent and Mantle Cell Lymphomas
Rituximab Followed by High-Dose Therapy With ASCT Effective as Salvage for Follicular Lymphoma
Results of a Prospective Phase II Trial of Limited and Extended Rituximab in Nodular Lymphocyte-Predominant Hodgkin’s Disease
CNS Prophylaxis Not Protective Against CNS Relapse in Aggressive Non-Hodgkin’s Lymphoma With Bone Marrow Involvement
Single-Agent Everolimus Active in Relapsed Aggressive Non-Hodgkin’s Lymphoma
Pretransplant Rituximab Improves Posttransplantation Survival But Does Not Impair Engraftment Among Patients With DLBCL
PINNACLE Update: Bortezomib Responses Confirmed in Patients With Relapsed/Refractory MCL
HyperCVAD Plus Rituximab Active in Newly Diagnosed MCL, Although Responses Not Durable and Regimen Associated With Considerable Toxicity
FIT Trial: ⁹⁰Y-Ibritumomab Consolidation Therapy Superior to Observation in Advanced Follicular Lymphoma
Abbreviated Chemoimmunotherapy After R-CHOP Feasible in PET-Negative Patients With Limited-Stage DLBCL

Expert Analysis

Lymphomas

Program Director:
Roy A. Beveridge, MD

Faculty:
Alexandra M. Levine, MD Carol S. Portlock, MD Julie M. Vose, MD

Moderator:
Robert S. Mocharnuk, MD

Learning Objectives

Upon completion of this activity, participants should be able to:

Describe recently reported clinical data on emerging treatments for follicular lymphoma
Explain the use of imaging for guiding treatment decisions in non-Hodgkin’s lymphoma and Hodgkin’s disease
Discuss efficacy and safety data from recent studies including patients with aggressive lymphomas

CME CREDIT INFORMATION

Release Date: 02/28/08

Expiration Date: 02/27/09

Physicians: maximum of 1.25 AMA PRA Category 1 Credit(s)™

Pharmacists: 1.2 contact hours (0.12 CEUs)

Registered Nurses: 1.2 Nursing CE credits

Status: Please log in to view status

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.